Boehringer Ingelheim has entered into a multi-year strategic partnership with TARGET PharmaSolutions, a real-world clinical data company, for an observational study TARGET-NASH.

This study is evaluating patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) and has enrolled 2,423 patients at 55 sites, with the expectation to enroll as many as 15,000 patients over the coming years.

The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, investigators, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes.

Meg Powell, chief executive officer of TARGET PharmaSolutions, said, “We are very excited to have Boehringer Ingelheim join TARGET-NASH as an industry partner.  We have exceeded our enrollment targets to date, and we are providing valuable real-world data and insight on NASH patients that will have a significant impact on the scientific understanding of the natural history and treatment modalities for NASH.  This data, combined with the TARGET-NASH biorepository and patient reported outcomes, will enable our collaborators to continue to increase their understanding of this growing disease.”